Some patients report modest weight changes of 1 to 3 pounds, likely related to reduced inflammation-driven fluid retention rather than fat loss
Changes in GLP-1 insurance coverage may be due to the rising costs to health plans of the medication and the recent FDA approval of generic versions of Victoza (liraglutide) and Byetta (exenatide)
But coverage is more nuanced than a yes-no decision. Insurers may respond to lower GLP-1 prices by increasing restrictions, which are already stringent, as Klebanoff showed in two studies with LDI Senior Fellows Jalpa Doshi and Judith Long, and colleagues
The excess body fat predisposes an obese individual to chronic diseases, such as coronary heart disease, type 2 diabetes and diseases of the gall bladder and cancer
When we offer a program, it's really going to be holistic and will include evaluation, counseling and medications but not just GLP-1s as there are generic medications out there that have been very successful in managing weight loss." Studies have shown that people who take blockbuster obesity drugs Ozempic or Wegovy will likely gain the weight back after they stop taking the medications
Your journey begins with a detailed consultation to understand your health, lifestyle, and goals
)
